NasdaqGS - Delayed Quote USD

Centessa Pharmaceuticals plc (CNTA)

13.20
+0.94
+(7.67%)
At close: May 20 at 4:00:01 PM EDT
13.20
0.00
(0.00%)
After hours: May 20 at 4:31:54 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2020
Total Revenue
15,000
0
6,853
0
0
Operating Expense
210,742
201,055
178,136
210,283
10,440
Operating Income
-195,742
-201,055
-171,283
-210,283
-10,440
Net Non Operating Interest Income Expense
8,877
3,926
570
-7,033
-378
Other Income Expense
-33,221
-35,784
-5,428
362
155
Pretax Income
-220,086
-232,913
-176,141
-216,954
-10,663
Tax Provision
3,760
2,844
-25,056
-747
--
Net Income Common Stockholders
-223,846
-235,757
-151,085
-216,207
-10,663
Diluted NI Available to Com Stockholders
-223,846
-235,757
-151,085
-216,207
-10,663
Basic EPS
-1.88
-2.06
-1.57
-2.31
-0.15
Diluted EPS
-1.88
-2.06
-1.57
-2.31
-0.15
Basic Average Shares
122,759.90
114,473.45
96,177.58
93,400.51
70,890.99
Diluted Average Shares
122,759.90
114,473.45
96,177.58
93,400.51
70,890.99
Total Operating Income as Reported
-195,742
-201,055
-171,283
-212,263
-10,440
Total Expenses
210,742
201,055
178,136
210,283
10,440
Net Income from Continuing & Discontinued Operation
-223,846
-235,757
-151,085
-216,207
-10,663
Normalized Income
-198,273.25
-210,184.25
-151,085
-214,233.82
-10,663
Interest Income
19,315
14,016
10,476
244
--
Interest Expense
10,438
10,090
9,906
7,277
378
Net Interest Income
8,877
3,926
570
-7,033
-378
EBIT
-209,648
-222,823
-166,235
-209,677
-10,285
EBITDA
-208,729
-221,881
-165,425
-209,546
-10,285
Reconciled Depreciation
919
942
810
131
0
Net Income from Continuing Operation Net Minority Interest
-223,846
-235,757
-151,085
-216,207
-10,663
Total Unusual Items Excluding Goodwill
-34,097
-34,097
0
-1,980
0
Total Unusual Items
-34,097
-34,097
0
-1,980
0
Normalized EBITDA
-174,632
-187,784
-165,425
-207,566
-10,285
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-8,524.25
-8,524.25
0
-6.82
0
12/31/2020 - 5/28/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PRAX Praxis Precision Medicines, Inc.
39.70
+6.29%
 
IDYA IDEAYA Biosciences, Inc.
19.63
+8.57%
 
ACLX Arcellx, Inc.
60.54
+3.47%
 
APGE Apogee Therapeutics, Inc.
40.34
+1.08%
 
DYN Dyne Therapeutics, Inc.
12.34
+5.83%
 
CRNX Crinetics Pharmaceuticals, Inc.
31.37
+1.36%
 
EWTX Edgewise Therapeutics, Inc.
14.87
+0.54%
 
TRML Tourmaline Bio, Inc.
16.20
-2.59%
 
VRDN Viridian Therapeutics, Inc.
13.82
+7.80%
 
PHVS Pharvaris N.V.
17.25
+3.36%